Senate Bill 682 aims to regulate the sale of hemp-derived cannabinoid products in Wisconsin by establishing specific definitions, requirements, and restrictions. The bill modifies the current definition of hemp to include hemp-derived cannabinoid products and specifies that testing for hemp must be conducted using high-performance liquid chromatography, gas chromatography-mass spectrometry, or other reliable methods. It introduces a new definition for hemp-derived cannabinoids, which includes various forms of THC, and outlines that these products must be intended for ingestion, inhalation, or skin absorption. Additionally, the bill prohibits the sale of these products to individuals under 21 years of age and establishes penalties for underage possession and misrepresentation of age.

To ensure consumer safety, the bill mandates that manufacturers submit samples of each batch of hemp-derived cannabinoid products to accredited laboratories for testing before sale. The laboratories must certify that the products meet specific criteria, including accurate labeling of cannabinoid content and absence of harmful substances. Furthermore, products must be accompanied by a certificate of analysis, which can be provided via a QR code on the label. The bill also requires that all hemp-derived cannabinoid products include detailed labeling information, such as manufacturer contact details, serving sizes, and potency, and mandates child-resistant packaging. Overall, the legislation seeks to create a safer marketplace for hemp-derived cannabinoid products while ensuring compliance with health and safety standards.

Statutes affected:
Bill Text: 94.55(1), 94.55